



Perforin detection as specific tumor marker for Urothelial Cancer in Patients

Hanan D. Abbas¹, Rawaa Abdul-Ameer Abdul-Jabbar²,

¹ Department of Basic Science, College of Dentistry- Kufa University.

² Department of Biology, College of Science, Al-Mustansiriyah University

Corresponding Author e-mail: hanan.alkillabi@uokufa.edu.iq

Abstract:

Background: Perforin "PRF1" is a fenestrae-framing peptide which has the capacity of "toxic lymphocytes", which slaughter changed cells as well as cells harboring intracellular pathogens (Voskoboinik and Trapani 2006). These lymphocytes traverse both the intrinsic and versatile safe compartments, and include "toxic T lymphocytes", regular executioner killer cells, Natural killer cells. These cells can release "PRF1" continuously sending warning signals. "PRF1" is placed in the cellular parts that are released in a cellular way to empty their contents, performing their role as target cells (Voskoboinik *et al* 2010).

The goal of this study is to discover a specific marker can detect or prevent superficial bladder cancer in men using malignant biopsies of bladder for this purpose.

Methods:

Envision technique was used on tissue samples taken from 15 men with urothelial cancer and 15 other men with benign were adopted as a control group. Cancer cells were inferred using perforin marker.

Results:

The results showed a significant increase ($P < 0.05$) in the level of perforin expression in malignant cells in contrast to that in benign cells which demonstrated negative level of perforin expression.

Conclusion:

It was concluded from the present study results the main role of perforin as a diagnostic marker in urothelial cancer disease, especially in the initial state of disease.

Keywords: Perforin, tumor marker, Urothelial Cancer.

Introduction

Perforin is a protein that forms cellular holes found in granules within lymphatic cells and when these granules decompose, perforin moves to the plasma membrane of the cell forming short chains and with calcium forming the cellular holes. The pore formed takes into consideration the aloof dispersion of a group of expert "apoptotic proteases", define as the "granzymes", through objective cell (Trapani 1996). Perforin has basic and utilitarian similitudes to supplement segment (C9) and the lytic film embeddings part of perforin (Tschopp *et al* 1986).

This locale imparts homology to cholesterol-subordinate cytolysins from Gram-positive bacteria (Rosado *et al* 2007). Such as "C9", perforin makes transmembrane tubules and is equipped for degrade non-particularly an assortment of goal cells. Perforin is expected to work through making openings in the cell membrane film which induce releasing a deluge of calcium and starts layer reconstitute systems which makes "perforin" in a primary internal some (Thiery *et al* 2011).

"Urinary bladder" malignancies constitute fifth driving reason for growth passing among guys in Western nations. The larger part (>90%) are urothelial carcinomas "UCs" (Eble *et al* 2004). Most of the mortality happens in persons who give intrusive "UCs", portrayed by a large invasion rate and wide broad comprehension for sub-atomic components hidden UC



attack, the primary occasion in metastasis, is expected to discover sub-atomic markers foreseeing malady movement and to create enhanced helpful focuses for treatment of obtrusive UCs (Black and Dinney 2007 ,Egeblad and Werb 2002 ,Obrien *et.al* 2008).

"Granzyme Gr B" is a serine proteinase contained, together with different Grs and "perforin PRF", in cellular vesicles of enacted "cytotoxic T lymphocytes CTLs" and common executioner "NK" cells (Russell 2002 and Ley ,Bleackley 2005) .On effector-target cell association, GrB is exocytosed and conveyed by methods for Perforin in the liquid cytoplasm "cytosol" of target cells, where it initiates the programmed cell death "apoptosis" through protein degradation of internal substrates (Chowdhury and Lieberman 2008 , Cullen and Martin 2008 , Besencare *et.al* 2008)

The present study was designed to estimate the content of perforin in tissue samples with urothelial cancer in an attempt to detect the possible role of perforin and to benefit from future results and their applicability in the diagnosis, prevention or treatment of this disease.

Materials and Methods:

Subjects and samples

The present investigation included 15 patients of Iraqi males with urothelial carcinoma and other 15 males with benign as control gather . The blood were taken from the patients at al sader therapeutic city healing facility in najaf, also biopsies have been taken for each patient. The patients were partitioned into four stages and three grades, the stages are Ta, T1, T2, T3, and the grades are I, II, III (WHO, 2010) , additionally into four subdivisions as indicated by ages (40-49Y), (50-59Y), (60-69Y), (70-80Y), and two subdivisions smokers and non smokers. The control bunch comprise of 15 benign tissue samples (biopsies) brought from patients with urothelial cancer.

Perforin assessment:

Envision system strategy have been utilized as a part of different strides for perforin location through immunohistochemical staining procedure by using blue hematoxyline stain , from essential counter acting agent to catalyst, to be refined in a single step.

Results:

The outcomes demonstrated the critical expanding of perforin expression in the urothelial malignant samples in examination with those of benign. The percent of expression expanded with the movement of the stage and the grade of tumor. The comes about likewise showed a noteworthy height of perforin expression in all periods of patients particularly assemble of (70-79Y). Result of smokers patients have clarified huge expression ($p < 0.05$) in examination with non-smokers patients (Table 1, Fig. 2,3).



Table (1) indicate higher percentages of perforin expression in advanced stages of disease (T3),(G3) ,also in older patients (70-80 Y),and in smoking conditions.

All cases	Number 15	Neg/weak %	Moderate %	Strong %	P value
Stages					
P Ta	8	10	44	46	
P T1	4	13	28	59	
P T2	2	9	25	66	
P T3	1	0	24	76	p< 0.05
Grades					
P G1	11	8	40	52	
P G2	3	18	41	41	
P G3	1	2	29	69	p< 0.05
Ages					
P (40-49 Y)	1	18	30	52	
P (50-59 Y)	2	12	30	58	p<0.05
P (60-69 Y)	10	18	19	63	
P (70-80 Y)	2	3	17	80	
Smoking					
P Smokers	10	5	33	62	p<0.05
P non-Smokers	5	76	11	13	

The paradigm for positive immunohistochemistry(IHC)was dull darker hasten at all cytoplasm ,The immunostaining demonstrated to immunoreactive cells per add up to size of malignantcells.Each test was checked with graduate power magnification.The immunohistochemicalstaining was assessed by Truls et al (2005).





Figure (1) (20x) cross histological section of normal human urinary bladder stained with perforin used as control, showing normal perforin content. U: urothelium, L: lamina propria, M: middle cells, B: basal cells.



(a)

(b)

Figure (2) cross histological section of malignant urinary bladder cells: (a 40x, b 10x) brown color refers to moderate epithelial perforin expression in patient G1, Ta.

Discussion:

Epithelial-mesenchymal progress "EMT" has risen like a first step in the intrusion of a several carcinomas (Thiery 2006) such as "UCs" (Lipponen and Eskelinen 1995, Lascombe *et al.* 2006, Baumgartner *et al.* 2007, Bryan *et al.* 2008).

A fundamental component of malignant tissues experiencing "EMT" is the absence of inter epithelial cell connections, bringing about a "mesenchymal-like phenotype" malignant cells are separated from adjacent cells and increment their versatility gridding corruption abilities, in this way moving and invading.

It has been accounted for that downregulation or absence of film "E-cadherin" (in charge of the loss of cell bond), might be joined by carcino-articulation of "N-cadherin", a protein found in the mesenchyme (Lascombe *et al.* 2006, Bryan *et al.* 2008).

Study of Donatella 2010 demonstrated that "Granzyme B" is a protein that has the ability of serine degradation released by "cytotoxic lymphocytes" stimulating apoptosis in the presence of perforin in effector cells and that urothelial malignancy growth lysates corrupted "ECM" segments, and this outcome is conversely with past information by Buzza *et al.* 2005, who, steady with GrB-interceded dividing of integrin-subordinate cell grip, have appeared in vitro restraint of growing malignant cells, movement and attack by "GrB".

The present examination uncovered profoundly expression rates of perforin in all stages and grades of urinary bladder malignancy cells (Table 1). study of Chia *et al.*

URL: <http://www.uokufa.edu.iq/journals/index.php/ajb/index>

<http://iasj.net/iasj?func=issues&jid=129&uiLanguage=en>

Email: biomgzn.sci@uokufa.edu.iq



2009 demonstrated that PRF1 is probably going to ensure people against hematological malignancies, starting at all "non-consanguineous" patients who are explained "bi-allelic PRF1" changes involving PRF1A91V.

Joseph *et.al* 2013 found a negligible increment during recurrence of "PRF1" changes upon high number of melanoma patients (including "PRF1A91V-positive" people, few other patients bearing the uncommon "PRF1R28C allele" and one patient conveying PRF1N252S), as contrasted and a solid, sex coordinated control populace.

perforin expression has been recognized in the epithelial and stromal cells of the urinary bladder lesions, and the epithelial cells might be the real wellspring of perforin articulation (Figure 2,3) and may be able to expand the movement of cancer. This result may concur with investigation of Lin *et. al.* (2011) which showed the overexpression of aromatase prompts expanded expansion in the urothelial layer.

Conclusion:

The present work showing that perforin after emission from tumor cells could go about as autocrine factors advancing neoplastic growth, and the perforin nonattendance in benign urinary bladder cells (Figure 1) may bolster this conclusion and may prompt utilize perforin as productive biomarker in the therapeutic administration to treat or counteract movement of urinary bladder malignancy and attack in men.

References:

Baumgart E, Cohen MS, Silva Neto B, Jacobs MA, Wotkowicz C, Rieger-Christ KM, Biolo A, Zeheb R, Loda M, Libertino JA, Summerhayes IC. Identification and prognostic significance of an epithelial-mesenchymal transition expression profile in human bladder tumors. *Clin Cancer Res* 2007; 13: 1685–89.

Beseničar MP, Metkar S, Wang B, Froelich CJ, Anderluh G. Granzyme B translocates across the lipid membrane only in the presence of lytic agents. *Biochem Biophys Res Commun* 2008; 371: 391–4.

Black PC, Dinney CPN. Bladder cancer angiogenesis and metastasis—translation from murine model to clinical trial. *Cancer Metastasis Rev* 2007; 26: 623–634.

Bleackley RC. A molecular view of cytotoxic T lymphocyte induced killing. *Biochem Cell Biol* 2005; 83: 747–51.

Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DM, Jankowski JA. Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. *J Pathol* 2008; 215: 184–94.

Buzza MS, Zamurs L, Sun J, Bird CH, Smith AI, Trapani JA, Froelich CJ, Nice EC, Bird PI. Extracellular matrix remodeling by human granzyme B via cleavage of vitronectin, fibronectin and laminin. *J Biol Chem* 2005; 280: 23549–558.

Chia J, Yeo KP, Whisstock JC, Dunstone MA, Trapani JA, Voskoboinik I (2009) Temperature sensitivity of human perforin mutants unmasks subtotal loss of cytotoxicity, delayed FHL, and predisposition to cancer. *Proc Natl Acad Sci USA*, 106: 9809–14.

Chowdhury D, Lieberman J. Death by a thousand cuts: granzyme pathways of programmed cell death. *Annu Rev Immunol* 2008; 26: 389–420.

Cullen SP, Martin S. Mechanisms of granule-dependent killing. *Cell Death Differ* 2008; 15: 251–62.



Donatella D ,Paola P ,Chiara R ,Cosimo D ,Stefania M ,Angela S ,Antonella S and Francesca V (2010) Granzyme B is expressed in urothelial carcinoma and promotes cancer cell invasion .Int.J.Cancer:127,1283-1294.

EbleJN, SauterG, EpsteinJI, SesterhennIA, eds. *World Health Organization (WHO) classification of tumors of the urinary system and male genital organs*. Lyon: IARC Press, 2004. 90–92.

Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. *Nat Rev Cancer* 2002; 2: 161–74.

Lascombe I, Clairotte A, Fauconnet S, Bernardini S, Wallerand H, Kantelip B, Bittard H. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. *Clin Cancer Res* 2006; 12: 2780–7.

Lin W, Rahman NA, Lin J, Zhang H, Gou K, Yu W, Zhu D, Li N, Huhtaniemi I and Li X(2011) Molecular mechanisms of bladder outlet obstruction in transgenic male mice overexpressing aromatase .*Am J Pathol* ,178:1233–1244.

Lipponen PK, Eskelinen MJ. Reduced expression of E-cadherin is related to invasive disease and frequent recurrence in bladder cancer. *J Cancer Res ClinOncol* 1995; 121: 303–8.

O'Brien P, O'Connor BF. Seprase: an overview of an important matrix serine protease. *BiochimBiophysActa* 2008; 1784: 1130–45.

Rosado CJ, Buckle AM, Law RH, Butcher RE, Kan WT, Bird CH, Ung K, Browne KA, Baran K, Bashtannyk-Puhlovich TA, Faux NG, Wong W, Porter CJ, Pike RN, Ellisdon AM, Pearce MC, Bottomley SP, Emsley J, Smith AI, Rossjohn J, Hartland EL, Voskoboinik I, Trapani JA, Bird PI, Dunstone MA, Whisstock JC (2007). "A common fold mediates vertebrate defense and bacterial attack". *Science*. **317** (5844): 1548–51.

Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. *Annu Rev Immunol* 2002; 20: 323–70.

Thiery J, Keefe D, Boulant S, Boucrot E, Walch M, Martinvalet D, Goping IS, Bleackley RC, Kirchhausen T, Lieberman J (2011). "[Perforin pores in the endosomal membrane trigger the release of endocytosed granzyme B into the cytosol of target cells](#)". *Nat. Immunol.* **12** (8): 770

Thiery JP. Complex networks orchestrate epithelial-mesenchymal transitions. *Nat Rev Mol Cell Biol* 2006; 7: 131–42.

Trapani JA (1996). "Target cell apoptosis induced by cytotoxic T cells and natural killer cells involves synergy between the pore-forming protein, perforin, and the serine protease, granzyme B". *Australian and New Zealand journal of medicine*. **25** (6): 793–9.

Truls, G., Kennet, W. and Jörgen, C. (2005) Analysis of Her2/neu Expression in Primary Bladder Carcinoma and Corresponding Metastases. *Journal of Pathology*, 95, 982-986

Tschopp J, Masson D, Stanley KK (1986). "Structural/functional similarity between proteins involved in complement- and cytotoxic T-lymphocyte-mediated cytolysis". *Nature*. **322** (6082): 831–4

Voskoboinik I ,Dunstone MA ,Baran K ,Whisstock JC ,Trapani JA (2010) Perforin :structure ,function , and role in human immunopathology.*Immunol Rev*,235 :35-54.

Voskoboinik I ,Smyth MJ and Trapani JA (2006) Perforin- mediated target-cell death and immune homeostasis .*Nat Rev Immunol* ,6:940-52.